Of note, ERK2 silencing slightly, but reproducibly, protected HME D13/+ cells, while ERK1 silencing even sensitized to SM83/CPT treatment and simultaneously increased Noxa basal levels especially in CRC cell lines. Here, MAPK3 is linked to colorectal carcinoma.